Promoting Recognition, Diagnosis, and Treatment of Cold Agglutinin Disease

Released On
September 1, 2021

Expires On
September 1, 2022

Media Type

Completion Time
60 minutes

Hematology-Oncology, Emergency Medicine

Bleeding Disorders, Hematology, Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Annenberg Center for Health Sciences at Eisenhower.

This activity is supported by an independent educational grant from Sanofi Genzyme.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours (including .75 pharmacology hour)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity was developed for adult hematologists, hematologist-oncologists, hematology-oncology nurse practitioners, emergency physicians, primary care physicians, and other clinicians involved in the management of patients with cold agglutinin disease.

Program Overview

Cold Agglutinin Disease is a rare, chronic hemolytic disorder, representing approximately 20% of all autoimmune hemolytic anemias. Catherine M. Broome, MD, and Alexander Röth, MD, provide an understanding of the pathogenesis of this disorder caused by cold-reacting IgM autoantibodies and reveal common clinical features. Because of the high mortality rate among those suffering from CAD, it is important to be aware of the diagnostic criteria, as well as the current and novel treatment options, with the goal of increasing hemoglobin levels, avoiding the need for transfusions, and improving circulatory symptoms. Dr. Broome discusses the most recent advancements in treatment based on global collaborative efforts and the importance of participating in the CADENCE Registry. Significant findings from the phase 3 CARDINAL trial are also presented along with an interactive case scenario.

Content Areas

  • Pathogenesis
  • Clinical Features
  • Diagnostic Markers
  • Treatment
  • CADENCE Registry
  • CARDINAL Trial

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe the pathogenesis of cold agglutinin disease (CAD), the mechanism of disease, its symptoms, and its possible consequences
  • Diagnose patients suspected of having CAD
  • Appropriately treat and monitor patients with CAD using nonpharmacologic and pharmacologic options
  • Describe the mechanism of action, safety and efficacy of new and emerging treatments for CAD



Catherine M. Broome, MD

Associate Professor of Medicine
Georgetown University
MedStar Georgetown University Hospital
Washington, DC


Alexander Röth, MD

Department of Hematology and Stem Cell Transplant
University Hospital Essen
University of Duisburg-Essen
Essen, Germany

Physician Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Nursing Credit Designation

A maximum of 1.0 contact hour, including .75 pharmacology hour, may be earned for successful completion of this activity.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.0 contact hour. To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Disclosures of Conflicts of Interest

Catherine M. Broome, MD

  • Speakers Bureau: Alexion, Apellis, Argenx, Sanofi

Alexander Röth, MD

  • Advisor: Alexion, Apellis, BioCryst, Novartis, Roche, Sanofi
  • Consultant: Alexion, Apellis, BioCryst, Novartis, Roche, Sanofi
  • Research Support: Roche
  • Speakers Bureau: Alexion, Novartis Sanofi

Additional content planners

Victoria Anderson (medical writer)

  • Stockholder: Abbott Laboratories, AbbVie

The following have no significant relationship to disclose:
Gene Cullen, MD (peer reviewer)
Heather Jimenez, FNP-C (nurse reviewer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved applications.


The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information

For help or questions about this activity please contact Continuing Education:

Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday